Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab induction therapy in moderate to severe ulcerative colitis (phase 2b/3)
CTR20200117Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in autoimmune colitis, sponsored by AbbVie Inc.. Started Mar 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20200117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200117.